EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer

Zhuanzhuan Mu iD, Xin Zhang iD, Di Sun iD, Yuqing Sun iD, Cong Shi iD, Gaoda Ju iD, Zhentian Kai iD, Lisha Huang iD, Libo Chen, Jun Liang iD, Yansong Lin iD

The Journal of Clinical Endocrinology & Metabolism · 19.04.2024 · 109 (5) · 1231-1240

DOI: 10.1210/clinem/dgad697 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 07.12.2023. Verfasst von Zhuanzhuan Mu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Acade…. Hauptthemen laut MEDLINE: Thyroid Neoplasms. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Project on Inter-Governmental International Scientific and Technological Innovation Cooperation, National Key Projects of Research and Development Plan, National High Level Hospital Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Patients with differentiated thyroid cancer (DTC) with distant metastasis (DM) are usually not recognized as radioactive iodine (RAI)-refractory DTC in a timely manner. The elucidation of genetic features related to RAI uptake patterns may shed light on the early recognition of RAI-refractory DTC.

Objective

This work aimed to elucidate the underlying molecular features behind different RAI uptake patterns.

Methods

A total of 214 patients with DM-DTC were retrospectively included in the analysis. RAI uptake patterns were defined as initially RAI refractory (I-RAIR) and initially RAI avid (I-RAIA) according to the first post-treatment scan, then I-RAIA was further divided into continually RAIA (C-RAIA), partly RAIR (P-RAIR), and gradually RAIR (G-RAIR) according to subsequent scans. The molecular subtype groups—BRAFV600E mutated, RAS mutated, fusions, and others—were classified according to main driver genes status.

Results

BRAF, TERT promoter, and TP53 mutations are more frequently detected in the I-RAIR pattern while RET fusions and RAS mutations are more frequent in the I-RAIA pattern. A late-hit mutation including TERT, TP53, or PIK3CA is more common in I-RAIR than that in I-RAIA (50.0% vs 26.9%, P = .001), particularly for those with RAS mutations in the I-RAIR group, always accompanied by TERT promoter. Isolated RET fusions accounts for 10% of I-RAIR. When compared among driver gene groups, BRAFV600E-mutated tumors have a higher rate of the I-RAIR pattern (64.4%) than RAS-mutated (4.5%, P < .001) and fusion-positive (20.7%, P < .001) tumors. In I-RAIA subgroups, BRAFV600E-mutated tumors have lower prevalence of the C-RAIA pattern than those with RAS mutation or fusions.

Conclusion

Patients with the I-RAIR pattern predominantly featured mutations of the BRAF and/or TERT promoter, of which RAS mutations were usually accompanied by late-hit mutations, while fusions mostly occurred alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsHumansIodine RadioisotopesRetrospective StudiesProto-Oncogene Proteins B-rafMutation

Stichwörter der Autor:innen

RAI uptake patterndifferentiated thyroid cancerdistant metastasesgenomic alteration

Substanzen

Iodine RadioisotopesProto-Oncogene Proteins B-raf

Autor:innen und Institutionen

  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College (PUMC) Hospital, Chinese Academy of Medical Sciences & PUMC, Beijing, 100730, China.
  • Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Beijing, 100730, China.
  • Department of Medical Oncology, Key Laboratory of Carcinogenesis & Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital and Institute, Beijing, 100142, China.
  • Department of Oncology, Peking University International Hospital, Peking University, Beijing, 102206, China.
  • Department of Bioinformatics, Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd, Shanghai, 201321, China.
  • Department of Medicine, Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd, Shanghai, 201321, China.

ORCID-Profile: Zhuanzhuan Mu, Xin Zhang, Di Sun, Yuqing Sun, Cong Shi, Gaoda Ju, Zhentian Kai, Lisha Huang, Jun Liang, Yansong Lin

Förderung

  • Project on Inter-Governmental International Scientific and Technological Innovation Cooperation
  • National Key Projects of Research and Development Plan
  • National High Level Hospital Clinical Research
  • National Natural Science Foundation of China

Zitieren

APA

Mu, Z., Zhang, X., Sun, D., Sun, Y., Shi, C., Ju, G., Kai, Z., Huang, L., Chen, L., Liang, J., & Lin, Y. (2024). Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 109(5), 1231-1240. https://doi.org/10.1210/clinem/dgad697

Vancouver

Mu Z, Zhang X, Sun D, Sun Y, Shi C, Ju G, et al. Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 2024;109(5):1231-1240. doi:10.1210/clinem/dgad697

BibTeX
@article{Mu2024,
  author = {Mu, Zhuanzhuan and Zhang, Xin and Sun, Di and Sun, Yuqing and Shi, Cong and Ju, Gaoda and Kai, Zhentian and Huang, Lisha and Chen, Libo and Liang, Jun and Lin, Yansong},
  title = {Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {109},
  number = {5},
  pages = {1231--1240},
  doi = {10.1210/clinem/dgad697}
}
Kostenlos starten →